Prometheus Biosciences And Dr. Falk Pharma Advance PR600 And Trigger Final Preclinical Milestone Payment

Published by
The Street

By GlobeNewswire SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced it has received its final preclinical milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize Prometheus’ second program, PR600. The milestone was based on Prometheus’ development of a propr…

Read More

Leave a Reply